Table 1.

Demographic data and clinical characteristics of the included subjects

	Control	HSCT	Natalizumab
n	9	12	15
Male/female	3/6	4/8	4/11
Age (years)	27 (24–37)	32 (16–41)	39 (18–67)
Total disease duration (months)	n/a	94 (44–170)	140 (17–393)
Disease duration after commencement of treatment (months)	n/a	53 (3–84)	24 (9–49)
Number of relapses in the year before treatment start	n/a	6·9	2·0
Annualized relapse rate after treatment	n/a	0·06	0·1

HSCT, haematopoietic stem cell transplant; n/a, not applicable.

Data for age, disease duration and duration of treatment are given as means (range). For HSCT-treated patients, duration of treatment equals time since HSCT.